TD Cowen Maintains its Buy Rating and $100 PT for DexCom, Inc. (DXCM)

With significant upside potential, DexCom, Inc. (NASDAQ:DXCM) secures a spot on our list of the 13 Best Quality Stocks to Buy According to Hedge Funds.

On September 25, 2025, given that previous technical problems with the company’s G7 continuous glucose monitoring (CGM) technology had been fixed, TD Cowen kept its buy rating and $100 price target for DexCom, Inc. (NASDAQ:DXCM).

According to a prominent opinion leader and corroborating comments from other industry professionals, analysts stated that the deployment and accuracy issues that were noted earlier this year have mostly been resolved. DexCom, Inc. (NASDAQ:DXCM) pointed out that previous G7 setbacks had no effect on market share, suggesting that the competitive impact was low.

The gadget has been improved by DexCom, Inc. (NASDAQ:DXCM)’s management, boosting trust in the dependability and functionality of the system. These improvements, according to TD Cowen, support the G7 system’s sustained adoption and expansion, strengthening the company’s position in the global CGM market and supporting its maintained rating and price target for the diabetes technology company.

The goal of DexCom, Inc. (NASDAQ:DXCM), a medical device company, is to create, develop, and market continuous glucose monitoring systems both domestically and abroad. It is one of the best quality stocks.

While we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.

Disclosure: None.